Refractory generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 70, Issue SUPPL. 2, 2009, Pages 32-38

  Pollack, Mark H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUSPIRONE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NIRAVAM; OLANZAPINE; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; CHRONIC DISEASE; COGNITIVE DEFECT; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ECONOMIC ASPECT; EMPLOYMENT; FAMILY RELATION; GENERALIZED ANXIETY DISORDER; HUMAN; HYPERTENSION; INSOMNIA; LIVER FUNCTION TEST; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; UNITED STATES; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; AZABICYCLO COMPOUNDS; BENZODIAZEPINES; BUSPIRONE; CHRONIC DISEASE; CITALOPRAM; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; MENTAL HEALTH SERVICES; NEUROBIOLOGY; NEUROPROTECTIVE AGENTS; PIPERAZINES; PREVALENCE; RECURRENCE; RILUZOLE; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 70349240864     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.s.7002.06     Document Type: Review

References (55)

1. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70(suppl 2):4-9.
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. (Pubitemid 40973434)
3. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. J Clin Psychiatry. 2001;62(suppl 11):15-19. (Pubitemid 32537573)
4. The World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva, Switzerland: The World Health Organization; 2007. Available at http://www.who.int/ classifications/apps/icd/icd10online/. Accessed Oct 21, 2008
5. Maier W, Gaensicke M, Freyberger HJ, et al. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? Acta Psychiatr Scand. 2000;101(1):29-36. (Pubitemid 30041121)
6. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171.
7. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12(6):355-362. (Pubitemid 20359656)
8. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry. 2009;70(suppl 2):20-24.
9. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(5):355-364. (Pubitemid 24176813)
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
11. Kessler RC, Brandenburg N, Lane M, et al. Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med. 2005;35(7):1073-1082. (Pubitemid 41015705)
12. Stein MB. Neurobiology of generalized anxiety disorder. J Clin Psychiatry. 2009;70(suppl 2):15-19.
13. De Bellis MD, Casey BJ, Dahl RE, et al. A pilot study of amygdala volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2000;48(1):51-57.
14. De Bellis MD, Keshavan MS, Shifflett H, et al. Superior temporal gyrus volumes in pediatric generalized anxiety disorder. Biol Psychiatry. 2002;51(7):553-562. (Pubitemid 34327330)
15. Quirk GJ, Armony JL, LeDoux JE. Fear conditioning enhances different temporal components of tone-evoked spike trains in auditory cortex and lateral amygdala. Neuron. 1997;19(3):613-624.
16. Keller M. Raising the expectations of long-term treatment strategies in anxiety disorders. Psychopharmacol Bull. 2002;36(suppl 2):166-174.
17. Yonkers KA, Dyck IR, Warshaw M, et al. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549. (Pubitemid 30353655)
18. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol. 1990;10(suppl 3):101S-110S. (Pubitemid 20212937)
19. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand Suppl. 1998;98(suppl 393):6-11.
20. Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. J Clin Psychiatry. 2009;70(suppl 2):10-14.
21. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003;54(9):1006-1011. (Pubitemid 36793455)
22. El-Mallakh RS, Hollifield M. Comorbid anxiety in bipolar disorder alters treatment and prognosis. Psychiatr Q. 2008;79(2):139-150.
23. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS Drugs. 2007;21(9):727-740. (Pubitemid 47294719)
24. Barger SD, Sydeman SJ. Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder? J Affect Disord. 2005;88(1):87-91.
25. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry. 1993;150(4):600-607. (Pubitemid 23109929)
26. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, comorbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):747-759.
27. Davidson JRT. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry. 2009;70(suppl 2):25-31.
28. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-895. (Pubitemid 23330980)
29. Rickels K, Wiseman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43(12, sec 2):81-86. (Pubitemid 13221551)
30. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl). 1991;105(3):428-432.
31. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350-357. (Pubitemid 32545557)
32. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9(5):495-505. (Pubitemid 44607202)
33. Montgomery SA, Sheehan DV, Meoni P, et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36(4):209-217. (Pubitemid 34626371)
34. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2008;18(9):673-681.
35. Browning M, Reid C, Cowen PJ, et al. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol. 2007;21(7):684-690. (Pubitemid 47437913)
36. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005; 62(9):1022-1030. (Pubitemid 41248382)
37. Rickels K, Pollack MH, Lydiard RB, et al. Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 21, 2002; Philadelphia, Pa. Abstract NR162:44.
38. Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2006;7(15):2139-2154.
39. Letterman L, Markowitz JS. Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy. 1999;19(5):565-567. (Pubitemid 29211801)
40. Pollack MH, Roy-Byrne PP, Van Ameringen M, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005;66(11):1401-1408. (Pubitemid 41779538)
41. Pollack MH, Tiller J, Xie F, et al. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008;28(3):308-316.
42. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47(4):170-174. (Pubitemid 16109750)
43. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211-215.
44. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321-1325. (Pubitemid 41546513)
45. Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40(3):41-57.
46. Hoge EA, Worthington JJ 3rd, Kaufman RE, et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522-527.
47. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27(2):207-210. (Pubitemid 46594942)
48. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(5):497-498. (Pubitemid 41368377)
49. Katzman MA, Vermani M, Jacobs L., et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22(8):1480- 1486.
50. Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008;197(4):675-681.
51. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27(2):596-601.
52. Mathew SJ, Amiel JM, Coplan JD, et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005;162(12):2379-2381. (Pubitemid 41740219)
53. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59:1052-1060. (Pubitemid 43849658)
54. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551-562. (Pubitemid 351645051)
55. Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med. 1999;29(6):1425- 1434.